Charles A. McWherter
Overview
Charles A. McWherter received an average of $1M in total compensation, including $385K in salary, at Cymabay Therapeutics from 2012 to 2022.
2022Cymabay TherapeuticsPresident of R&D
2021Cymabay TherapeuticsPresident of R&D
2019Cymabay TherapeuticsChief Scientific Officer
2018Cymabay TherapeuticsChief Science Officer
2017Cymabay TherapeuticsSenior Vice President and Chief Scientific Officer
2016Cymabay TherapeuticsSenior Vice President and Chief Scientific Officer
2015Cymabay TherapeuticsSenior Vice President and Chief Scientific Officer
2013Cymabay TherapeuticsSenior Vice President and Chief Scientific Officer
2012Cymabay TherapeuticsSenior Vice President and Chief Scientific Officer
Source: SEC filings on April 19, 2023, May 15, 2020, April 26, 2019, April 20, 2018, April 19, 2017, and April 21, 2014.
Related executives
We found nine more executives who work or worked at Cymabay Therapeutics.
Sujal Shah
Cymabay Therapeutics
Chief Executive Officer
Paul Quinlan
Cymabay Therapeutics
General Counsel
Dennis Kim
Cymabay Therapeutics
Chief Medical Officer
Lewis Stuart
Cymabay Therapeutics
Chief Commercial Officer
Janet Dorling
Cymabay Therapeutics
Former Chief Commercial Officer
Pol Boudes
Cymabay Therapeutics
Chief Medical Officer
Klara Dickinson
Cymabay Therapeutics
Chief Regulatory and Compliance Officer
Daniel Menold
Cymabay Therapeutics
Vice President, Finance
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019